ClinicalTrials.gg
Not yet recruitingNCT07943117Updated Nov 17, 2026

Videocapillaroscopic Findings in Hand Osteoarthritis

An observational study in Osteearthritis and Capillaroscopy, sponsored by Bandırma Onyedi Eylül University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Bandırma Onyedi Eylül University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Osteoarthritis with a site in Turkey — 23 open to participants now, 30 under way, none of them phase 3. Osteoarthritis · Turkey.

Planned enrollment
8th of 42
130 · median 84
Started
2026
with 13 others
Observational
42 of 106
11 open now
Primary completion
2027-04
later than 24 of 29 live
Registered
106th of 106
by date

Among the 106 studies in Osteoarthritis with a site in Turkey, this one is the 8th largest by planned enrollment of the 42 observational ones that give a count, is one of 14 that started in 2026, is one of 42 observational ones, reaches primary completion later than 24 of the 29 other live ones, and was the 106th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

23 of the 106 studies in Osteoarthritis with a site in Turkey are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoarthritis with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of this study is to compare microvascular changes-assessed via nailfold videocapillaroscopy-in patients with primary hand osteoarthritis against a healthy control group, and to investigate the relationship between capillaroscopic findings and disease severity, functional status, and clinical characteristics.

Read the detailed description

In this context, the associations between capillaroscopic parameters and the Kellgren-Lawrence radiological grading, handgrip strength, the Functional Index for Hand Osteoarthritis (FIHOA), and the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) scores will be evaluated. Furthermore, the study aims to determine the potential clinical value of nailfold videocapillaroscopy in identifying microvascular alterations associated with primary hand osteoarthritis.

03

Conditions studied

  • Osteearthritis
  • Capillaroscopy

Browse trials for

Keywords

  • Osteoarthritis
  • Hand
  • Microscopic Angioscopy (Capillaroscopy)
  • Microcirculation
  • Hand Strength
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population will consist of patients diagnosed with primary hand osteoarthritis and age- and sex-matched healthy controls. Participants will undergo clinical assessment, hand function evaluation, radiographic assessment, and nailfold videocapillaroscopy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient group (Primary hand osteoarthritis)

    • Being 18 years of age or older.
    • Having a diagnosis of primary hand osteoarthritis in accordance with the 2018 EULAR recommendations.
    • Being willing to participate in the study and having signed the written Form.
    • Being able to undergo clinical assessment, nailfold videocapillaroscopy, and the necessary functional evaluations.
    • Having hand radiographs of sufficient quality to be evaluated according to the Kellgren-Lawrence classification system.

Healthy control group

  • Being 18 years of age or older.
  • Having no diagnosis of inflammatory rheumatologic disease or primary hand osteoarthritis.
  • Being willing to participate in the study and having signed the written Informed Consent Form.
  • Being similar to the patient group in terms of age and gender.
  • Being able to undergo nailfold videocapillaroscopy assessment.

Exclusion criteria

Exclusion Criteria:

  • Patient group

    • Being under 18 years of age.
    • Diagnosis of secondary osteoarthritis of the hand (due to trauma, infection, metabolic, or other causes).
    • Presence of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, inflammatory myopathies, vasculitis, or other connective tissue diseases.
    • History of Raynaud's phenomenon.
    • History of .
    • Chronic renal failure (stage 4-5) or advanced liver failure.
    • Active infection or a serious infection within the last four weeks.
    • Pregnancy or breastfeeding.
    • History of a neurological condition that could affect hand grip strength (e.g., hemiplegia, tetraplegia, peripheral nerve injury, or other neurological/neuromuscular disorders resulting in loss of muscle strength).
    • History of trauma, surgical intervention, or any procedure affecting the nail bed of the fingers within the last month.
    • Presence of an open wound, active infection, severe dermatological condition, or deformity that would hinder the assessment of the nail fold.
    • Refusal to participate in the study or failure to sign the form.

Healthy control group

In addition to the exclusion criteria listed above:

  • Diagnosis of primary osteoarthritis of the hand or any inflammatory rheumatic disease.
  • Presence of hand pain or any chronic musculoskeletal disorder that affects hand function.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
130 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • hand osteoarthritis group

    hand osteoarthritis group; * Being 18 years of age or older. * Having a diagnosis of primary hand osteoarthritis in accordance with the 2018 EULAR recommendations. * Being willing to participate in the study and having signed the written Informed Consent Form. * Being capable of undergoing clinical assessment, nailfold videocapillaroscopy, and the necessary functional evaluations. * Having hand radiographs of sufficient quality to be evaluated according to the Kellgren-Lawrence classification system.

  • control group

    control group; * Being 18 years of age or older. * Absence of a diagnosis of inflammatory rheumatic disease or primary osteoarthritis of the hand. * Willingness to participate in the study and having signed the written Informed Consent Form. * Having characteristics similar to the patient group in terms of age and gender. * Being able to undergo the nailfold videocapillaroscopy assessment.

06

What researchers measure

Primary outcomes

  1. Nailfold videocapillaroscopic microvascular parameters

    The primary outcome is the comparison of nailfold videocapillaroscopic microvascular parameters between patients with primary hand osteoarthritis and healthy controls. Nailfold videocapillaroscopy will be performed using the Dino-Lite Capillary Scope Pro200 digital microscope and DinoCapture v2.0 software. Prior to the examination, participants will be required to rest for at least 15 minutes in a room maintained at a constant temperature of 20-22°C; they will also be instructed to refrain from smoking or consuming caffeine for at least 30 minutes before the procedure. Participants will be questioned regarding any recent manicures, nail-biting, local trauma, or other procedures that might affect the nail bed. During the examination, the hands will be kept at the level of the heart, and immersion oil will be applied to the nailfold. The second through fifth digits of both hands will be evaluated at ×200 magnification, and images of two 1 mm areas from each digit will be recorded.

    Time frame: 6 months

Secondary outcomes

  1. Kellgren-Lawrence classification

    Participants' hand radiographs will be evaluated for signs of osteoarthritis. The presence of osteophytes, joint space narrowing, subchondral sclerosis, cystic changes, and deformities in the distal interphalangeal, proximal interphalangeal, and first carpometacarpal joints will be recorded. The radiological severity of the disease will be graded from 0 to 4 for each joint using the Kellgren-Lawrence classification: grade 0, no radiological evidence of osteoarthritis; grade 1, questionable joint space narrowing and possible osteophytes; grade 2, definite osteophytes and possible joint space narrowing; grade 3, multiple osteophytes, definite joint space narrowing, sclerosis, and possible bone contour deformity; and grade 4, severe joint space loss, large osteophytes, marked sclerosis, and bone deformity. Radiographic hand osteoarthritis will be defined, in general, as a Kellgren-Lawrence grade of ≥2.

    Time frame: 6 months

  2. Australian/Canadian Osteoarthritis Hand Index (AUSCAN)

    Disease-related pain, stiffness, and functional impairment will be assessed using the Australian/Canadian Osteoarthritis Hand Index (AUSCAN). AUSCAN is a 15-item, patient-reported outcome measure developed for hand osteoarthritis, comprising subscales for pain (5 items), morning stiffness (1 item), and physical function (9 items). The function subscale evaluates difficulty with activities of daily living, such as turning on a faucet, operating a doorknob, buttoning clothes, opening a jar, carrying heavy objects, and grasping small items. The scale can be administered using Likert, visual analog, or numerical rating formats; the specific version and scoring method to be used in this study will be standardized in advance. Higher scores indicate more severe symptoms and greater loss of function.

    Time frame: 6 months

  3. Functional Index for Hand Osteoarthritis (FIHOA/Dreiser Index)

    Functional impairment due to hand osteoarthritis will also be assessed using the Functional Index for Hand Osteoarthritis (FIHOA/Dreiser Index). The FIHOA is a 10-item scale that evaluates daily hand functions, such as using a key, cutting with a knife, opening a bottle or jar, buttoning, writing, lifting objects, and shaking hands. Each item is scored on a scale of 0-3, with a total score ranging from 0-30; a higher score indicates greater functional impairment. The validity and reliability of the Turkish version of the FIHOA have been established, and it has been reported to demonstrate high internal consistency and test-retest reliability.

    Time frame: 6 months

  4. Handgrip strength

    Grip strength will be measured separately for each hand using a standard hand dynamometer (Baseline brand, 200 lb LITE hydraulic hand dynamometer). During the measurement, the participant will be in a seated position, with the shoulder in adduction and neutral rotation, the elbow flexed at approximately 90°, the forearm in a neutral position, and the wrist in slight extension. Three measurements will be taken for each hand, with short rest intervals between them; the analysis will utilize either the mean of these measurements or the highest value, in accordance with a pre-established protocol. The brand and model of the dynamometer used will be specified in the research form. Grip strength measurements obtained via a hand dynamometer have been shown to be reliable in patients with hand osteoarthritis.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Fioravanti A, Tofi C, Cerase A, Priolo F, Marcolongo R. Capillaroscopic findings in erosive and nodal osteoarthritis of the hands. Clin Rheumatol. 2001;20(3):174-6. doi: 10.1007/s100670170059. PubMed 11434467 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers due to patient confidentiality and data privacy considerations. Only anonymized aggregate data may be reported in the publication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Apr 20, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943117
Lead sponsor
Bandırma Onyedi Eylül University
Responsible party
Nurten NAS KIRDAR (Assistant professor, Bandırma Onyedi Eylül University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Apr 20, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Nurten NAS KIRDAR, Assistant Professor
Contact
nkirdar@bandirma.edu.tr
+905415511691
Ayşegül ÖZDOĞAN BİRCAN, Specialist Physician
Contact
Nurten NAS KIRDAR
principal investigator · Bandırma Onyedi Eylül University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion